Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Norwegian clinical-stage biotech Nykode Therapeutics revealed that it has received notification from Genentech, a US ...

Nykode Therapeutics (VACBF) announced last night that it has received notification from Genentech, a member of the Roche (RHHBY), of its ...

Nykode Therapeutics (VACBF) announced last night that it has received notification from Genentech, a member of the Roche (RHHBY), of its decision to terminate the collaboration and licensing ...

Adding Nykode Therapeutics' VB10.16 vaccine to treatment with Roche's cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies, which demonstrated favorable safety and efficacy results from its Phase 2 trial for ...

Meanwhile, another company focused on advanced cervical cancer is Nykode Therapeutics, its VB10.16 vaccine to treatment with Roche’s cancer immunotherapy Tecentriq reported in May this year to ...

development of novel immunotherapies, will host a webcast this morning to provide an update on VB10.NEO. The presentation will be followed by a Q&A ...